C. Jack

Combining Raw Score and Normative Score Cut-Offs for Remote Digital Cognitive Screening: Impact on Sensitivity and Specificity in Cognitively Unimpaired Participants and Participants With Mild Cognitive Impairment and Dementia

Objective: The Mayo Test Drive (MTD) screening battery is a digital, self-administered, web-based cognitive assessment (Stricker et al., 2025 TCN). We aimed to compare diagnostic accuracy of raw versus normative score approaches to distinguishing cognitively unimpaired (CU) from mild cognitive impairment/mild dementi...

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

The recent approval of disease-modifying therapies for symptomatic Alzheimer's disease is a major advance for a condition with few therapeutic options. Anti-amyloid monoclonal antibodies have shown clinically meaningful benefits in slowing cognitive decline. Clinical trials in symptomatic Alzheimer's disease suggest th...

Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer’s disease PET imaging biomarkers

INTRODUCTIONCognitive characterization is increasingly important for Alzheimers disease treatment decisions, highlighting the need for scalable cognitive assessment. We evaluated the diagnostic accuracy of a remote self-administered cognitive screening battery, Mayo Test Drive (MTD), across clinically and biologically...

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

Neuroimaging is now a cornerstone of Alzheimer's disease care and a crucial discriminator tool for characterising brain injury across the lifespan and with emerging fluid biomarkers, neuroimaging supports accurate diagnosis, prognosis, and treatment monitoring.

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease

Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

CSF proteomics and machine learning reveal distinct stages across the Alzheimer’s disease continuum

These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.

Concordance Between [18F]Flortaucipir PET Visual Reads and CenTauR-Based Quantification.

Generalized additive models examined clinical progression on the basis of visual and CenTauRz-based assessments of tau PET positivity and highlighted the need for new quantification approaches to better capture the complex patterns of tau deposition, important for early AD detection and monitoring.

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

A pathobiological definition of disease is proposed to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.

Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer's disease across diverse participants

Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown.

Perivascular Spaces as Determinants of Amyloid, Tau, and Vascular Biomarker Progression.

Findings lend support for PVS-BG as an early indicator of small vessel dysfunction and WMH pathogenesis and suggest that PVS-BG may identify individuals at increased risk of progressive SVD.

Diffusion MRI identifies a prolonged Pre-WMH Phase in Cerebral Small Vessel Disease

Diffusion MRI biomarkers were abnormal at least a decade before WMH abnormality in the population, revealing a prolonged phase of early SVD and highlighting their potential for SVD prevention.